Evidence map›Paper›PMID 40562540›Full record

ArticleLife science alliance2025

DEK promotes mammary hyperplasia and is associated with H3K27me3 epigenetic modifications.

Megan E Johnstone, Ashley L Leck, Taylor E Lange, Katherine E Wilcher, Miranda S Shephard, Aditi Paranjpe, Sophia Schutte, Susanne I Wells, Ferdinand Kappes, Nathan Salomonis and 1 more

Abstract read
In one paragraph

Article in Life science alliance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Megan E JohnstoneDivision of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Ashley L LeckDivision of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Taylor E LangeDivision of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Katherine E WilcherDivision of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Miranda S ShephardDivision of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Aditi ParanjpeInformation Services for Research, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Sophia SchutteDivision of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Susanne I WellsDivision of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Ferdinand KappesDivision of Natural and Applied Sciences, Duke Kunshan University, Kunshan, Jiangsu, China.ORCID 0000-0002-0369-0065
Nathan SalomonisDivision of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Lisa M Privette VinnedgeDivision of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA Lisa.Privette@cchmc.org.

Funding

Training Program in Cancer TherapeuticsT32CA117846 · NCI · UNIVERSITY OF CINCINNATI · PI PRICE, CAROLYN M, TAKIAR, VINITA · 2006 to 2022
$6.5M
Mechanisms coupling DEK to oncogenesisR37CA218072 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI PRIVETTE VINNEDGE, LISA M. · 2018 to 2024
$2.5M
Defining genetic and metabolic requirements of aggressive breast cancerR01CA239697 · NCI · UNIVERSITY OF CINCINNATI · PI WALTZ, SUSAN E, WELLS, SUSANNE I · 2020 to 2024
$2.4M
Training Program in Basic and Translational OncologyT32CA298951 · NCI · UNIVERSITY OF CINCINNATI · PI Vinita Takiar, Susan E Waltz · 2025 to 2026
$776k
NCI NIH HHS R01 CA239697NCI NIH HHS R37 CA218072NCI NIH HHS T32 CA117846NCI NIH HHS T32 CA298951
6 · The paper itself

Abstract

The DEK chromatin remodeling protein has oncogenic functions in breast cancers, but its functional role in normal mammary gland epithelium has remained unexplored. We developed two novel genetically engineered mouse models to study the role of Dek in normal mammary gland biology in vivo. Mammary gland-specific Dek transgenic mice developed hyperplasia and had a transcriptional profile that revealed increased expression of cell cycle, mammary stem/progenitor, and lactation-associated genes. Conversely, Dek knockout mice exhibited mammary gland functional defects resulting in dramatically reduced pup survival. Analysis of previously published scRNA-sequencing of mouse mammary glands revealed that

Indexed as

Chromosomal Proteins, Non-HistoneEpigenesis, GeneticHistonesMammary Glands, AnimalOncogene ProteinsPoly-ADP-Ribose Binding ProteinsAnimalsCell CycleCell ProliferationDNA-Binding ProteinsEnhancer of Zeste Homolog 2 ProteinEpithelial CellsFemaleHyperplasiaMiceMice, KnockoutChromosomal Proteins, Non-HistoneDEK protein, mouseDNA-Binding ProteinsEnhancer of Zeste Homolog 2 ProteinEzh2 protein, mouseHistonesOncogene ProteinsPoly-ADP-Ribose Binding Proteins

Identifiers

PMID40562540
PMCPMC12198979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.